Comment by doctorpangloss
15 days ago
i haven't read the article. is the question, can hims ship a clone of 25mg oral wegovy? yes, it can.
> ... at oral doses <15mg/day.
well it's not a clone of rybelsus, it's a clone of wegovy 25mg. so i suppose it will be bioavailable at 25mg.
> That's a very brand-new interpretation of rules
this is true. Tidmarsh, the whole Novo Nordisk deal with Trump, it's now about, well we'll do the patent enforcement we didn't want to do before. The simple fact of the matter is, these are lifestyle products, so it's not so black and white if they ought to have the same patent and payment protections as typical therapeutics.
> well it's not a clone of rybelsus, it's a clone of wegovy 25mg. so i suppose it will be bioavailable at 25mg.
No. RTFA. Feed it into an LLM with the first thought off the top of your head. Skim it quick. Whatever. (tl;dr: the clone skips the ingredient that makes the contents bioavailable)
i have a feeling that what actually happened is that absence of the ingredient in the text that the article is talking about is a documentation error, and that's why the FDA makes no mention about it at all (as you discovered). i think the thing that is getting shipped has the ingredient and this is a nothingburger.
indeed, the only evidence that the clone is missing the ingredients is the guy read a Reuters article about it, and asked the chatbot (presumably) to do research. the clones in this sector are pretty faithful. i'm going to chalk it up to, "declined to elaborate" doesn't mean, as the author insinuates, that Hims has a bad clone, i think they just didn't answer the question and there's nothing more to this.
this is coming from my place as knowing a lot about this sector and the simple fact of the matter is, they just make a clone and they do it faithfully.
“What’s more likely is they’re sitting on an unknown breakthrough that took pharmaceutical companies billions and years and just launched.” - you sure you read it this time?